US20110039928A1 - Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition - Google Patents
Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition Download PDFInfo
- Publication number
- US20110039928A1 US20110039928A1 US12/806,436 US80643610A US2011039928A1 US 20110039928 A1 US20110039928 A1 US 20110039928A1 US 80643610 A US80643610 A US 80643610A US 2011039928 A1 US2011039928 A1 US 2011039928A1
- Authority
- US
- United States
- Prior art keywords
- fatty acid
- creatine
- cetyl
- composition according
- cetylated fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 229960003624 creatine Drugs 0.000 title claims abstract description 23
- 239000006046 creatine Substances 0.000 title claims abstract description 23
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 23
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 23
- 239000000194 fatty acid Substances 0.000 title claims abstract description 23
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 23
- 239000003513 alkali Substances 0.000 title claims abstract description 10
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 6
- 230000037406 food intake Effects 0.000 claims abstract description 7
- 230000000699 topical effect Effects 0.000 claims abstract description 4
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- DYIOQMKBBPSAFY-BENRWUELSA-N Palmityl myristoleate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCC DYIOQMKBBPSAFY-BENRWUELSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 229940093532 cetyl myristoleate Drugs 0.000 claims description 4
- DYIOQMKBBPSAFY-UHFFFAOYSA-N palmityl myristoleate Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCC=CCCCC DYIOQMKBBPSAFY-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- JYTMDBGMUIAIQH-UHFFFAOYSA-N hexadecyl oleate Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC JYTMDBGMUIAIQH-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- JYTMDBGMUIAIQH-ZPHPHTNESA-N palmityl oleate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC JYTMDBGMUIAIQH-ZPHPHTNESA-N 0.000 claims description 2
- YEHRXIRYXGNEDS-PEZBUJJGSA-N palmityl palmitoleate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCC YEHRXIRYXGNEDS-PEZBUJJGSA-N 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 208000002193 Pain Diseases 0.000 description 14
- 230000036407 pain Effects 0.000 description 14
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 5
- 201000002481 Myositis Diseases 0.000 description 4
- 208000018937 joint inflammation Diseases 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010033425 Pain in extremity Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000024764 elbow pain Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention refers to a composition composed of a cetylated fatty acid and alkali buffered creatine for reducing joint and muscle related inflammation.
- Pain reducing medications are utilized daily, essentially to combat the symptoms of immune-related aging issues. Unfortunately, prescription drugs are not without side effects and many consumers are turning or have already turned to over-the-counter (OTC) substances in the hopes of obtaining pain relief without those side effects.
- OTC over-the-counter
- the present invention relates to an anti-inflammatory composition for treatment of inflamed joints.
- This composition includes an alkali buffered creatine and a cetylated fatty acid.
- the composition can be used for treating inflammation either by oral ingestion or by topical treatment.
- the present invention relates to an oral, alkali buffered creatine and cetylated fatty acid composition for reducing joint and muscle inflammation.
- the fatty acids bonded with the creatine get into the bloodstream and are delivered to the inflamed joint.
- the cell lipid structure surrounding the joint are lubricated by the fatty acids allowing the creatine to work more effectively in reducing inflammation.
- a preferred embodiment of the present invention utilizes an alkalyn buffered creatine sold under the trade name Kre-Alkalyn® by All American Pharmaceutical and Natural Foods Corporation. This creatine is then mixed, bonded, reacted or compounded with a cetylated fatty acid as follows:
- Formulation 1 Kre-Alkalyn ® creatine 500 mg Soy Bean Oil 250 mg Cetyl Myristoleate 250 mg
- the Kre-Alkalyn® creatine is an alkalyn buffered creatine.
- the soybean oil is a fatty acid and is used as a base.
- the cetyl myristoleate is a member of the cetylated fatty acid family.
- Kre-1 alkali buffered-creatine—cetylated fatty acid composition
- a total of 35 subjects (21 males, 14 females), each experiencing isolated areas of joint/muscle inflammation/pain, were divided into 2 groups: Group A was assigned four capsules of Kre-1 daily, Group B, an equal number of placebo capsules. The duration of the study was 30 days.
- Kre-1 exerts it greatest impact on areas of inflammation/pain in the extremities, as well as in the neck and shoulder region.
- the results of this study show that a combination of a cetylated fatty acid and an alkali buffered creatine provides an effective non-prescription material for reduction of pain and stiffness of the extremities, neck and shoulder regions in humans. It is intended that members of the cetylated fatty acid family including cetyl myristoleate, cetyl mylistate, cetyl palmitoleate, cetyl laureate, cetyl plamitate and cetyl oleate could be used equally as well.
- the cetylated fatty acids have anti-inflammatory properties with the ability to suppress pro-inflammatory cytokines.
- the alkali buffered creatine positively affects endothelial permeability, thereby inhibiting potentially inflammatory stimulating molecules from adhering and expressing their action as endothelial cells.
- the creatine/fatty acid composition may preferably occur through ingestion. It is contemplated that the creatine/fatty acid composition may be formulated such as a liquid drink and allow for oral ingestion. Further, the creatine/fatty acid composition may be formulated including solid formulations such as granules, a tablet, a capsule and the like for oral ingestion. Further, a food supplement such as a sports bar, and the like, may be employed for delivery of the creatine/fatty acid composition.
- formulations such as an emulsion, suspension and the like may be employed and allow delivery of the creatine/fatty acid composition to an inflamed joint.
- formulations allow application through a variety of methods such as topical applications including ointments, lotions, creams and gels.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
An anti-inflammatory composition for treatment of inflamed joints. This composition includes an alkali buffered creatine and a cetylated fatty acid. The composition can be used for treating inflammation either by oral ingestion or by topical treatment.
Description
- This application claims the benefit of provisional application Ser. No. 61/274,175 filed Aug. 13, 2009.
- The present invention refers to a composition composed of a cetylated fatty acid and alkali buffered creatine for reducing joint and muscle related inflammation.
- Chronic inflammation and muscle pain affects the body's ability to execute fluid motion. Ensuing joint stiffness restricts range of motion (ROM), which in turn negatively impacts quality of life (QOL). Chronic inflammation is a primary reason for doctor visits and increased costs in our healthcare system. Thousands of “Baby Boomers” born between 1946 and 1950, are now transitioning through age 60 and beyond. Along with the prospect of living to the century mark, comes the reality that osteoarthritis, sports and non-sports related injuries also increase. This year, the Arthritis Foundation has estimated that immune-related joint degenerative conditions are expected to strike more than 27 million Americans during the next decade, with additional untold numbers afflicted with ligament weakness, fibromyalgia, idiopathic pains and muscle trauma. Pain reducing medications are utilized daily, essentially to combat the symptoms of immune-related aging issues. Unfortunately, prescription drugs are not without side effects and many consumers are turning or have already turned to over-the-counter (OTC) substances in the hopes of obtaining pain relief without those side effects.
- It has been found that creatine is helpful in reducing inflammation as discussed in U.S. Publication No. 2009/0137669. Further, cetylated fatty acids have been reported to exhibit anti-inflammatory activity in joint and muscle regions.
- It would be desirable to provide a composition which would deliver cetylated fatty acids and alkali buffered creatine to a joint for treating inflammation.
- The present invention relates to an anti-inflammatory composition for treatment of inflamed joints. This composition includes an alkali buffered creatine and a cetylated fatty acid. The composition can be used for treating inflammation either by oral ingestion or by topical treatment.
- The present invention relates to an oral, alkali buffered creatine and cetylated fatty acid composition for reducing joint and muscle inflammation. When taken orally, the fatty acids bonded with the creatine get into the bloodstream and are delivered to the inflamed joint. The cell lipid structure surrounding the joint are lubricated by the fatty acids allowing the creatine to work more effectively in reducing inflammation.
- A preferred embodiment of the present invention utilizes an alkalyn buffered creatine sold under the trade name Kre-Alkalyn® by All American Pharmaceutical and Natural Foods Corporation. This creatine is then mixed, bonded, reacted or compounded with a cetylated fatty acid as follows:
-
-
Formulation 1: Kre-Alkalyn ® creatine 500 mg Soy Bean Oil 250 mg Cetyl Myristoleate 250 mg - The Kre-Alkalyn® creatine is an alkalyn buffered creatine. The soybean oil is a fatty acid and is used as a base. The cetyl myristoleate is a member of the cetylated fatty acid family.
- Clinical tests were performed to determine the efficacy of this formulation.
- Determine if a unique oral, alkali buffered-creatine—cetylated fatty acid composition (Kre-1), (a) is capable of reduce chronic joint and muscle related inflammation/pain, (b) can address site-specific pain with equal effectiveness, and, (c) will increase range of motion (ROM) in the afflicted area.
- A total of 35 subjects (21 males, 14 females), each experiencing isolated areas of joint/muscle inflammation/pain, were divided into 2 groups: Group A was assigned four capsules of Kre-1 daily, Group B, an equal number of placebo capsules. The duration of the study was 30 days.
- Participants entrance and exit interviews were conducted in the conference center at the All American Pharmaceutical. Study information (informed consent, test and placebo materials) was provided by an administrative assistant at All American Pharmaceutical. Pre and post blood tests (creatinine, AST, C-reactive protein) were accomplished at a local Laboratory Corporation of America blood lab. Physical examinations (entrance and exit), blood pressures, ROM, target area tenderness assessments, scoring and review of personal ‘Pain Journals’ by the test subjects and physicians were conducted at the Yellowstone Naturopathic Clinic, in Billings, Mont.
- Group A (n=24; age 55 +/−32 yrs) received Kre-1, and ‘Group B’ (n=11; age 45 +/−15 yrs) received the placebo.
- Data indicated approximately: 100% of ankle and foot pain, 80-85% of neck, shoulder, elbow, wrist, and hand pain, 71% of knee pain, respondents rated Kre-1 better than/as good as a prescription product in its ability to reduce/eliminate pain. Hip and back pain scores were no better than placebo scores for the same areas. ‘Group A’ experienced a modest increase in mobility (35%), but no measurable increase in ROM over that experienced in the placebo group (Group B).
- Kre-1 exerts it greatest impact on areas of inflammation/pain in the extremities, as well as in the neck and shoulder region.
-
TABLE 1 Oral Kre-1 for Joint and Muscle Inflammation - Study Data Participants: Group A (Kre-1) Group B (Placebo) Initial 24 11 Completing 20 (21)* 11 Gender 17 males/3 females 4 males/7 females Age 23-88 years Drop outs (M/F) 3 F 0 Entrance blood tests: Overall average creatinine 0.9 mg/dl 0.8 mg/dl 23 IU/L AST (SGOT) 4.1 mg/dl 6.2 mg/dl 22 IU/L C-reactive Protein Exit blood tests: Overall average creatinine 0.9 mg/dl 0.8 mg/dl AST (SGOT) 25 IU/L 21 IU/L C-reactive Protein 4.2 mg/L 5.1 mg/L Pain Relief: Per Area: Percentage of participants rating Ankle/Foot - 100% (2/2) 0% their treatment, “as good as” or Knee (and leg) - 71+% (5/7) 0% “better than” their usual OTC or Hip - 33% (1/3) 33% (1/3) prescription pain reliever Back - 50% (5/10) 0% Neck/Shoulders - 85+% (6/7) 33% (1/3) Elbow/Wrist/Hand 80% (4/5) 33% (1/3) No Pain Relief: Per Area: Percentage of participants rating Ankle/Foot - 0% 100% (3/3) their treatment, “not as good as” or Knee (and leg) - 29% (2/7) 100% (5/11) “didn't work” compared to their Hip - 67% (2/3) 66% (2/3) usual OTC or prescription pain Back - 50% (5/10) 100% (1/1) reliever Neck/Shoulders - 15% (1/7) 66% (2/3) Elbow/Wrist/Hand 20% (1/5) 66% (2/3) Overall Average Yes No Yes No Personally said they experienced 60% 40% 27% 73% reduced pain/increased mobility (12/20) (8/20) (3/11) (8/11) Blood Pressure: Overall Average Entrance Systolic/Diastolic 127/83 129/82 Exit Systolic/Diastolic 125/75 119/77 *This participant withdrew before the end of the study. -
TABLE 2 Kre-1 for Joint and Muscle Inflammation - Physicians Reports Pain: Group A (Kre-1) Group B (Placebo) Decrease 90% (18/20) 36% (4/11) No Change 10% (2/20) 55% (6/11) - The results of this study show that a combination of a cetylated fatty acid and an alkali buffered creatine provides an effective non-prescription material for reduction of pain and stiffness of the extremities, neck and shoulder regions in humans. It is intended that members of the cetylated fatty acid family including cetyl myristoleate, cetyl mylistate, cetyl palmitoleate, cetyl laureate, cetyl plamitate and cetyl oleate could be used equally as well. The cetylated fatty acids have anti-inflammatory properties with the ability to suppress pro-inflammatory cytokines. The alkali buffered creatine positively affects endothelial permeability, thereby inhibiting potentially inflammatory stimulating molecules from adhering and expressing their action as endothelial cells.
- Delivery of the creatine/fatty acid composition may preferably occur through ingestion. It is contemplated that the creatine/fatty acid composition may be formulated such as a liquid drink and allow for oral ingestion. Further, the creatine/fatty acid composition may be formulated including solid formulations such as granules, a tablet, a capsule and the like for oral ingestion. Further, a food supplement such as a sports bar, and the like, may be employed for delivery of the creatine/fatty acid composition.
- In addition, other formulations such as an emulsion, suspension and the like may be employed and allow delivery of the creatine/fatty acid composition to an inflamed joint. These formulations allow application through a variety of methods such as topical applications including ointments, lotions, creams and gels.
- While the fundamental novel features of the invention have been shown and described, it should be understood that various substitutions, modifications, and variations may be made by those skilled in the arts, without departing from the spirit or scope of the invention. Accordingly, all such modifications or variations are included in the scope of the invention as defined by the following claims:
Claims (8)
1. An anti-inflammatory creatine composition comprising an alkali buffered creatine and a cetylated fatty acid.
2. The composition according to claim 1 wherein the cetylated fatty acid includes at least one of cetyl myristoleate, cetyl mylistate, cetyl palmitoleate, cetyl laureate, cetyl plamitate and cetyl oleate.
3. The composition according to claim 1 formed in a solid form capable of ingestion.
4. The composition according to claim 3 wherein the solid form is configured as at least one of a food supplement, a tablet, a granule and a capsule.
5. The composition according to claim 1 formed in a liquid form capable of ingestion.
6. The composition according to claim 1 suitable for being received by topical application.
7. The composition according to claim 6 suitable for being received by at least one of a suspension, an emulsion and a solution.
8. The composition according to claim 7 which is configured as at least one of an ointment, lotion, cream and gel.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/806,436 US20110039928A1 (en) | 2009-08-13 | 2010-08-12 | Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition |
| US14/120,457 US9968581B2 (en) | 2009-08-13 | 2014-05-20 | Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27417509P | 2009-08-13 | 2009-08-13 | |
| US12/806,436 US20110039928A1 (en) | 2009-08-13 | 2010-08-12 | Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/120,457 Continuation US9968581B2 (en) | 2009-08-13 | 2014-05-20 | Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20110039928A1 true US20110039928A1 (en) | 2011-02-17 |
Family
ID=43086357
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/806,436 Abandoned US20110039928A1 (en) | 2009-08-13 | 2010-08-12 | Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition |
| US14/120,457 Active US9968581B2 (en) | 2009-08-13 | 2014-05-20 | Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/120,457 Active US9968581B2 (en) | 2009-08-13 | 2014-05-20 | Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition |
Country Status (2)
| Country | Link |
|---|---|
| US (2) | US20110039928A1 (en) |
| EP (1) | EP2283836A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016134150A1 (en) * | 2015-02-18 | 2016-08-25 | Tersus Life Sciences, LLC | Methods for improving joint function |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITUB20153130A1 (en) * | 2015-08-14 | 2017-02-14 | Pharmanutra S P A | Cetylated fatty acids, plant for their preparation and their use |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4113881A (en) * | 1976-05-03 | 1978-09-12 | Harry Weldon Diehl | Method of treating rheumatoid arthritis |
| US6159485A (en) * | 1999-01-08 | 2000-12-12 | Yugenic Limited Partnership | N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use |
| US6168802B1 (en) * | 1996-05-31 | 2001-01-02 | The Howard Foundation | Compositions containing creatine and aloe vera extract |
| US6274161B1 (en) * | 1996-05-31 | 2001-08-14 | The Howard Foundation | Compositions containing creatine in suspension |
| US6399661B1 (en) * | 2000-06-26 | 2002-06-04 | Jeffrey M. Golini | Oral creatine supplement and method for making same |
| US6432929B1 (en) * | 1999-06-22 | 2002-08-13 | Joint Juice, Inc. | Cartilage enhancing food supplements and methods of preparing the same |
| WO2003049687A2 (en) * | 2001-12-06 | 2003-06-19 | Weller Health, Inc. | Medicinal compositions & therapeutic methods |
| US20030212130A1 (en) * | 2000-09-14 | 2003-11-13 | Miller Donald W. | Creatine ester anti-inflammatory compounds and formulations |
| US20060062849A1 (en) * | 2004-09-21 | 2006-03-23 | Medical Research Institute | Oral formulation of creatine derivatives and method of manufacturing same |
| US20060216251A1 (en) * | 2005-03-24 | 2006-09-28 | Tracie Martyn International, Llc | Topical formulations and methods of use |
| US20090005450A1 (en) * | 2007-04-09 | 2009-01-01 | Belinda Tsao Nivaggioli | Use of creatine compounds for the treatment of eye disorders |
| US20090105196A1 (en) * | 2007-06-22 | 2009-04-23 | Belinda Tsao Nivaggioli | Use of creatine compounds to treat dermatitis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6417227B1 (en) * | 1999-04-28 | 2002-07-09 | Cg And Associates | Methods of delivery of cetyl myristoleate |
| AU1953701A (en) * | 1999-12-09 | 2001-06-18 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
| US6677321B1 (en) * | 1999-12-09 | 2004-01-13 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
| DE10032964B4 (en) * | 2000-07-06 | 2017-10-12 | Beiersdorf Ag | Use of creatine in cosmetic or dermatological preparations |
| US7772279B2 (en) * | 2002-03-21 | 2010-08-10 | Botanoceuticals, Inc. | Use of vegetable butter-based cetyl myristoleate for treating osteoarthritis and other musculoskeletal disease conditions and injuries |
-
2010
- 2010-08-12 US US12/806,436 patent/US20110039928A1/en not_active Abandoned
- 2010-08-13 EP EP10172826A patent/EP2283836A1/en not_active Ceased
-
2014
- 2014-05-20 US US14/120,457 patent/US9968581B2/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4113881A (en) * | 1976-05-03 | 1978-09-12 | Harry Weldon Diehl | Method of treating rheumatoid arthritis |
| US6168802B1 (en) * | 1996-05-31 | 2001-01-02 | The Howard Foundation | Compositions containing creatine and aloe vera extract |
| US6274161B1 (en) * | 1996-05-31 | 2001-08-14 | The Howard Foundation | Compositions containing creatine in suspension |
| US6159485A (en) * | 1999-01-08 | 2000-12-12 | Yugenic Limited Partnership | N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use |
| US6432929B1 (en) * | 1999-06-22 | 2002-08-13 | Joint Juice, Inc. | Cartilage enhancing food supplements and methods of preparing the same |
| US6399661B1 (en) * | 2000-06-26 | 2002-06-04 | Jeffrey M. Golini | Oral creatine supplement and method for making same |
| US20090137669A1 (en) * | 2000-09-14 | 2009-05-28 | Miller Donald W | Creatine ester anti-inflammatory compounds and formulations |
| US20030212130A1 (en) * | 2000-09-14 | 2003-11-13 | Miller Donald W. | Creatine ester anti-inflammatory compounds and formulations |
| WO2003049687A2 (en) * | 2001-12-06 | 2003-06-19 | Weller Health, Inc. | Medicinal compositions & therapeutic methods |
| US20060062849A1 (en) * | 2004-09-21 | 2006-03-23 | Medical Research Institute | Oral formulation of creatine derivatives and method of manufacturing same |
| US20060216251A1 (en) * | 2005-03-24 | 2006-09-28 | Tracie Martyn International, Llc | Topical formulations and methods of use |
| US20090005450A1 (en) * | 2007-04-09 | 2009-01-01 | Belinda Tsao Nivaggioli | Use of creatine compounds for the treatment of eye disorders |
| US20090105196A1 (en) * | 2007-06-22 | 2009-04-23 | Belinda Tsao Nivaggioli | Use of creatine compounds to treat dermatitis |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016134150A1 (en) * | 2015-02-18 | 2016-08-25 | Tersus Life Sciences, LLC | Methods for improving joint function |
| US10058524B2 (en) | 2015-02-18 | 2018-08-28 | Tersus Life Sciences, LLC | Methods for improving joint function |
| EP3258928A4 (en) * | 2015-02-18 | 2018-10-10 | Tersus Life Sciences, LLC | Methods for improving joint function |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150011631A1 (en) | 2015-01-08 |
| US9968581B2 (en) | 2018-05-15 |
| EP2283836A1 (en) | 2011-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nilsson et al. | A five-ingredient nutritional supplement and home-based resistance exercise improve lean mass and strength in free-living elderly | |
| Sanz-Paris et al. | Role of oral nutritional supplements enriched with B-hydroxy-B-methylbutyrate in maintaining muscle function and improving clinical outcomes in various clinical settings | |
| Warholm et al. | The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: a double-blind, randomized, placebo-controlled clinical trial | |
| Azizi et al. | Comparison of the effect of topical use of Nigella Sativa oil and diclofenac gel on osteoarthritis pain in older people: A randomized, double-blind, clinical trial | |
| US6908630B2 (en) | Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2 | |
| Benson et al. | Improvement of joint range of motion (ROM) and reduction of chronic pain after consumption of an ergothioneine-containing nutritional supplement | |
| Essouiri et al. | Effectiveness of argan oil consumption on knee osteoarthritis symptoms: a randomized controlled clinical trial | |
| Coppola et al. | Osteoarthritis: insights into diagnosis, pathophysiology, therapeutic avenues, and the potential of natural extracts | |
| Xie et al. | Safety, tolerability, and pharmacokinetics of ibuprofenamine hydrochloride spray (NSAIDs), a new drug for rheumatoid arthritis and osteoarthritis, in healthy Chinese subjects | |
| US9968581B2 (en) | Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition | |
| AU2021218215B2 (en) | Enzyme composition for management of metabolic health | |
| Marmitt | Potential plants for inflammatory dysfunction in the SARS-CoV-2 infection | |
| US20200078435A1 (en) | Use of low molecular weight collagen hydrolysate for preventing and/or reducing joint pain, lateral meniscal protusion and/or improving cartilage abrasion grade | |
| Li et al. | The effects of black soybean (Glycine max var.) on chronic cervical pain of sedentary office workers in a northern Chinese population | |
| Amorndoljai et al. | A clinical study phase II of ginger extract in nanostructured lipid carrier for pain relief in knee osteoarthritis patients | |
| Sharma et al. | Management strategies for Janu Sandhigata Vata vis-a-vis osteoartheritis of knee: A narrative review | |
| Jamadagni et al. | Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial | |
| Kenzaka et al. | Acute crystal deposition arthritis of the pubic symphysis | |
| Vaidya et al. | Efficacy and Safety of Boswellia serrata and Apium graveolens L. Extract Against Knee Osteoarthritis and Cartilage Degeneration: A Randomized, Double-blind, Multicenter, Placebo-Controlled Clinical Trial | |
| US20230248755A1 (en) | Compositions for improving joint health | |
| JP7690140B2 (en) | Collagen hydrolysate composition for reducing post-exercise joint pain - Patents.com | |
| ES2899548B2 (en) | KUKOAMINE A FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTION, PREFERABLY BY CORONAVIRUS | |
| Bagatela et al. | Safety and Efficacy KollaGen II-xs: A 60-day Clinical Trial. | |
| Pérez-Piñero et al. | Effectiveness of a Cucumber Extract Supplement on Articular Pain in Patients with Knee Osteoarthritis: A Randomized Double-Blind Controlled Clinical Trial | |
| Khalid | The effect of freeze dried whole raspberries on pain, joint flexibility, and inflammation in individuals with symptomatic knee osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |